Argenx Se (ARGX) EBIT (2016 - 2026)
Argenx Se (ARGX) posted EBIT of $394.0 million for Q1 2026, up 7.18% on a QoQ basis from $367.6 million in Q4 2025, and up 183.45% year-over-year from $139.0 million in Q1 2025.
Argenx Se (ARGX) EBIT (2016 - 2026) Analysis & Trends
Argenx Se's EBIT history runs 11 years deep, the most recent figure standing at $394.0 million for Q1 2026.
- Quarterly EBIT rose 183.45% year-over-year to $394.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 521.0% YoY) and the FY2025 annual result came in at $1.1 billion, up 4966.57% from the prior year.
- EBIT was $394.0 million for Q1 2026 at Argenx Se, up from $367.6 million in the prior quarter.
- Across five years, EBIT topped out at $394.0 million in Q1 2026 and bottomed at -$222.7 million in Q1 2022.
- A 5-year average of $16.5 million and a median of -$80.6 million in 2023 frame the typical range for EBIT.
- Annual changes were most pronounced in 2022 — EBIT tumbled 3036.48% — and 2025, when it jumped 2340.22%.
- Argenx Se's EBIT stood at -$114.4 million in 2022, then dropped by 21.14% to -$138.6 million in 2023, then soared by 174.33% to $103.0 million in 2024, then jumped by 256.76% to $367.6 million in 2025, then grew by 7.18% to $394.0 million in 2026.
- Business Quant data shows ARGX's EBIT at $394.0 million in Q1 2026, $367.6 million in Q4 2025, and $346.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 268.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 394.00 Mn |
| Dec 31, 2025 | 367.61 Mn |
| Sep 30, 2025 | 346.19 Mn |
| Jun 30, 2025 | 201.06 Mn |
| Mar 31, 2025 | 139.00 Mn |
| Dec 31, 2024 | 103.04 Mn |
| Sep 30, 2024 | 14.19 Mn |
| Jun 30, 2024 | -45.46 Mn |
| Mar 31, 2024 | -93.42 Mn |
| Dec 31, 2023 | -138.62 Mn |
| Sep 30, 2023 | -80.59 Mn |
| Jun 30, 2023 | -102.09 Mn |
| Mar 31, 2023 | -103.74 Mn |
| Dec 31, 2022 | -114.43 Mn |
| Sep 30, 2022 | -208.64 Mn |
| Jun 30, 2022 | -174.54 Mn |
| Mar 31, 2022 | -222.73 Mn |
| Dec 31, 2021 | -230.91 Mn |
| Sep 30, 2021 | 7.11 Mn |
| Jun 30, 2021 | 13,000,000.50 Bn |